ZUMA-3: A phase 1/2 multi-center study evaluation the safety and efficacy of KTE-C19 anti-CD19 CAR T cells in adult patients with relapsed/refractory B precursor acute lymphoblastic leukemia (R/R ALL)

被引：4

作者：

Shah, B. ^{[1
]}

Castro, J. ^{[2
,3
]}

Goekbuget, N. ^{[4
]}

Kersten, M. Jose ^{[5
]}

Hagenbeek, T. ^{[5
]}

Wierda, W. ^{[6
]}

Schiller, G. ^{[7
]}

Bot, A. ^{[8
]}

Rossi, J. M. ^{[8
]}

Jiang, Y. ^{[8
]}

Navale, L. ^{[8
]}

Stout, S. ^{[8
]}

Aycock, J. ^{[8
]}

Wiezorek, J. ^{[8
]}

Jain, R. ^{[8
]}

机构：

[1] H Lee Moffitt Canc Ctr & Res Inst, Dept Hematol Malignancies, Tampa, FL USA

[2] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA

[3] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA

[4] Goethe Univ Frankfurt, Dept Med 2, Frankfurt, Germany

[5] Univ Amsterdam, Acad Med Ctr, Dept Hematol, Amsterdam, Netherlands

[6] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

[7] Univ Calif Los Angeles, Ctr Hlth Sci, NA, Los Angeles, CA 90024 USA

[8] Kite Pharma, Santa Monica, CA USA

来源：

关键词：

D O I：

10.1093/annonc/mdw368.58

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

415TiP

引用

页数：1